vTv Therapeutics (VTVT) has received a new Buy rating, initiated by BTIG analyst, Thomas Shrader.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thomas Shrader has given his Buy rating due to a combination of factors surrounding vTv Therapeutics’ lead candidate, cadisegliatin. This drug, designed for type 1 diabetes, is a liver-selective glucokinase activator that has shown promise in improving glucose homeostasis. It holds a Breakthrough Therapy Designation and is currently in a Phase 3 trial, with expectations for the drug to significantly reduce hypoglycemic events.
Cadisegliatin’s potential market impact is substantial, with projected peak sales exceeding $500 million. The drug demonstrated a favorable safety profile in earlier trials, reducing hypoglycemia without increasing the risk of ketoacidosis. The valuation of vTv Therapeutics is supported by a $40 price target, based on a blend of discounted cash flow and peak multiple valuations, reflecting confidence in the company’s future growth and the drug’s commercial viability.
In another report released on November 7, H.C. Wainwright also maintained a Buy rating on the stock with a $36.00 price target.